The combination of gefitinib (n = 7) and erlotinib (n = 12) with pembrolizumab was evaluated in a phase I/II KEYNOTE-021 trial in advanced NSCLC patients with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.